Form 4: Neurocrine Biosciences Officer Eiry Roberts Reports Stock Transactions

Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting events.

Summary

• On February 13 and 14, 2025, Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, engaged in multiple transactions involving the company's common stock.
• These transactions included the acquisition of shares through the exercise of stock options and vesting of restricted stock units (RSUs), as well as the disposition of shares through market sales.
• The sales were executed under Rule 10b5-1 trading plans adopted on March 15, 2023, and June 14, 2024.
• Roberts sold 1,114 shares at a weighted average price of $116.9049, 604 shares at $116.7391 and 500 shares at $115.0425.
• Roberts also acquired 2,113 shares, 1,120 shares and 1,372 shares through option exercise and RSU vesting at $0.
• Following these transactions, Roberts directly owns 35,640 shares of Neurocrine Biosciences common stock.
• She also holds options for 43,261 shares and 8,108 restricted stock units.
• 34,455 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there is no indication of significant concern or excitement about the company's prospects.

Positives

• The vesting of restricted stock units and exercise of stock options indicate continued alignment of the officer's interests with the company's performance.
• The officer continues to hold a significant number of shares, options and RSUs in the company.

Negatives

• The sale of shares, even under a pre-arranged plan, could be interpreted negatively by some investors, although it is a common practice for executives to diversify their holdings.

Risks

• Continued sales of shares by the officer could put downward pressure on the stock price.
• Changes in the company's performance or outlook could affect the value of the officer's holdings and future transactions.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are often scrutinized by investors for insights into management's perspective on the company's future prospects. Sales under 10b5-1 plans are generally viewed as less informative, as they are pre-arranged and intended to avoid accusations of insider trading.

Comparison to Industry Standards

• Comparing the trading activity of Neurocrine's executives to those of similar biotechnology companies like Biogen, Vertex Pharmaceuticals, and Amgen can provide context.
• For example, if executives at these companies are also selling shares under 10b5-1 plans, it suggests a broader trend of diversification or personal financial planning.
• Conversely, if executives at competitor companies are primarily buying shares, it could signal a stronger belief in their company's growth prospects.
• The size and frequency of these transactions should also be compared to industry averages to determine if they are typical or unusual.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price due to the sales.
• The vesting of RSUs and stock options could be viewed positively by employees as it represents a form of compensation and alignment with the company's success.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Eiry Roberts, Form 4, Stock Options, Restricted Stock Units, Insider Trading, 10b5-1 Plan, Chief Medical Officer, Stock Sale, Stock Acquisition